Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
126 hedge funds and large institutions have $142M invested in Lumos Pharma, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 40 increasing their positions, 35 reducing their positions, and 23 closing their positions.
265% more call options, than puts
Call options by funds: $14.9M | Put options by funds: $4.08M
14% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 35
3% less funds holding
Funds holding: 130 → 126 (-4)
13% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 23
27% less capital invested
Capital invested by funds: $196M → $142M (-$53.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$3.83M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$3.37M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.64M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$1.61M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$16.9M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$13.8M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$6.45M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$3.94M |
| 5 |
PA
Perceptive Advisors
New York
|
-$3.65M |
LUMO Hedge Fund Activity: Q1 2018 in Review
126 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q1 2018, worth a combined $142M — down 27% from $196M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of LUMO and 20 opened new positions — a net loss of 3 holders — while 35 trimmed existing stakes and 40 added.
The largest buyer was JP Morgan Chase, adding an estimated $3.83M. The largest seller was Millennium Management, cutting an estimated $16.9M.
- 126 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q1 2018, down from 130 in Q4 2017.
- Funds reported $142M of Lumos Pharma, Inc. Common Stock stock for Q1 2018, down 27% quarter-over-quarter.
- 20 funds opened new Lumos Pharma, Inc. Common Stock positions in Q1 2018 and 23 closed out, a net change of -3 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q1 2018 was JP Morgan Chase, an estimated $3.83M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q1 2018 was Millennium Management, an estimated $16.9M sold.
Based on aggregated 13F filings for Q1 2018.